Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma

Inclusion Criteria

• •1. Age 18-70 years old, no gender and race limited;
• •2. Estimated life expectancy \> 12 weeks deemed by investigator；
• •3. CD19 were positive by histopathology and/or cytology diagnosis；
• •4. Patients with relapsed and/or refractory non-Hodgkin's B cell lymphoma (r/r B-NHL)；
• •5. Relevant indicators for disease or assessment within 4 weeks after the last treatment;
• •6. Quality of Life Score (KPS) \>50%；
• •7. Subject has adequate organ function at screening, cardiac ejection fraction ≥ 40%, no evidence of pericardial effusion as determined by an echocardiogram (ECHO); serum ALT/ AST \<3 upper limit of normal (ULN); bilirubin\<2.0 mg/dl; serum creatinine ≤1.6 mg/dl and/or BUN ≤ 1.5 mg/dl;
• •8. No remission or relapse after hematopoietic stem cell transplantation or autologous somatic immunotherapy;
• •9. Unsuitable conditions for stem cell transplantation;
• •10. Signed informed consent form (ICF).